Here’s why the Botanix (ASX:BOT) share price is slipping today

Botanix was busy over the fourth quarter, but its accomplishments aren’t being well received by the market.
The post Here’s why the Botanix (ASX:BOT) share price is slipping today appeared first on The Motley Fool Australia. –

The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is dipping after the company released its latest quarterly report.

The cannabinoid-focused pharmaceutical dermatology company’s quarter seemed to be a good one, but the market has reacted poorly.

Right now, the Botanix share price is 7.8 cents – 3.7% lower than its previous close.

Let’s take a closer look at today’s news from Botanix.

The news driving the Botanix share price

The Botanix share price is sliding despite the company’s productive quarter that ended on 30 June. Let’s take a look at what it was up to over the period.

Financial update

Botanix provided a brief financial update on its performance this quarter.  

The company stated it had $21.6 million in cash at the end of the quarter. That’s enough to fund an estimated 12.8 future quarters.

During the quarter, it had net cash outflows of around $1.7 million and it invested roughly $1.2 million in research and development activities.

New drugs

The Botanix share price is dipping despite plenty of productivity over the 3 months ended 30 June.

Botanix launched the Phase 1B rosacea clinical study trial for its BTX 1702 product in June.

The trial is investigating the safety and tolerability of different concentrations of BTX 1702 over an 8-week period.

It’s currently being hampered by COVID-19 restrictions. The company’s looking at adding more trial sites to minimise the impact of potential future lockdowns.

Additionally, Botanix announced positive results from its BTX 1204A pilot study in canines with atopic dermatitis during the quarter.

The company said atopic dermatitis in canines is similar to that in humans and that the study’s results are a good indication the treatment could be transferable.

Also, during the quarter Botanix launched the next phase of its BTX 1801 development program.

The program is aiming to help the nasal decolonisation of Staphylococcus aureus in haemodialysis patients.

It hopes BTX 1801 will help to prevent bloodstream infections in those undergoing haemodialysis, of which the company says there’s an “urgent need and significant market opportunity”.

Botanix Pharmaceuticals share price snapshot

The Botanix share price hasn’t been having a great year so far on the ASX.

It is currently 39% lower than it was at the start of 2021. However, it has gained 58% since this time last year.

The company has a market capitalisation of around $78 million, with approximately 973 million shares outstanding.

The post Here’s why the Botanix (ASX:BOT) share price is slipping today appeared first on The Motley Fool Australia.

Should you invest $1,000 in Botanix Pharmaceuticals right now?

Before you consider Botanix Pharmaceuticals , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Botanix Pharmaceuticals wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

More reading

Blazing it? How the top ASX cannabis shares performed in FY21

The Botanix (ASX:BOT) share price jumped 20% today

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!